{"id":"at-the-discretion-of-the-investigator","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3544774","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"At the discretion of the investigator, the exact mechanism of action is not provided.","oneSentence":"The mechanism of this drug is not specified.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:45.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"At the discretion of the investigator"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT05554393","phase":"PHASE2","title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Acute Myeloid Leukemia","enrollment":153},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT03712605","phase":"PHASE3","title":"Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-15","conditions":"Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","enrollment":280},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":"Gram-negative Bacterial Infections","enrollment":48},{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT05373940","phase":"NA","title":"Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-29","conditions":"Heart Failure, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator","enrollment":730},{"nctId":"NCT03874052","phase":"PHASE1","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Jennifer Saultz","startDate":"2019-08-16","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT06781125","phase":"PHASE1, PHASE2","title":"One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2026-03-18","conditions":"Malignant Solid Tumors","enrollment":72},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT06922955","phase":"","title":"A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aerin Medical","startDate":"2025-02-28","conditions":"Nasal Airway Obstruction","enrollment":400},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT04899661","phase":"","title":"A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-08-06","conditions":"Renal Anemia","enrollment":1081},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT06900374","phase":"NA","title":"Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2025-06-12","conditions":"Vaginal Dryness, Breast Cancer, Vulvovaginal Atrophy","enrollment":75},{"nctId":"NCT07217496","phase":"PHASE1","title":"N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer","status":"WITHDRAWN","sponsor":"Vadim S Koshkin","startDate":"2026-02-15","conditions":"Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT01612351","phase":"PHASE2","title":"Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":32},{"nctId":"NCT06408935","phase":"PHASE3","title":"Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients","status":"RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2024-04-17","conditions":"Crohn's Disease","enrollment":112},{"nctId":"NCT03901963","phase":"PHASE3","title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-26","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT07471841","phase":"PHASE2","title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","status":"NOT_YET_RECRUITING","sponsor":"Timothy Pardee","startDate":"2026-05","conditions":"IDH1 Mutation, Relapsed / Refractory AML","enrollment":25},{"nctId":"NCT06334120","phase":"","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-09-25","conditions":"Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer","enrollment":600},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT04301089","phase":"PHASE2","title":"Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-18","conditions":"Anxiety","enrollment":61},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT02829918","phase":"PHASE2","title":"Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-10-05","conditions":"Biliary Tract Cancer, Biliary Tract Neoplasms","enrollment":54},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT07455734","phase":"PHASE1, PHASE2","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Advanced Solid Tumor Cancer","enrollment":533},{"nctId":"NCT05326932","phase":"NA","title":"Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial","status":"RECRUITING","sponsor":"The George Institute for Global Health, China","startDate":"2022-11-03","conditions":"Acute Ischemic Stroke","enrollment":382},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT06931340","phase":"PHASE3","title":"Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-12-01","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":1260},{"nctId":"NCT07450183","phase":"PHASE2","title":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","status":"NOT_YET_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2026-06-01","conditions":"Lung Cancer (NSCLC)","enrollment":33},{"nctId":"NCT07195591","phase":"PHASE3","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","status":"RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2025-12-10","conditions":"Glioblastoma","enrollment":766},{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04852887","phase":"PHASE3","title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-07","conditions":"Stage I Breast Cancer","enrollment":1670},{"nctId":"NCT07166094","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","status":"RECRUITING","sponsor":"Genmab","startDate":"2025-11-28","conditions":"Endometrial Cancer, Recurrent or Progressive Endometrial Cancer","enrollment":544},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT07206056","phase":"PHASE1, PHASE2","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-15","conditions":"Progressive Metastatic Castrate Resistant Prostate Cancer","enrollment":188},{"nctId":"NCT07441512","phase":"PHASE2","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","status":"NOT_YET_RECRUITING","sponsor":"Hu Hai","startDate":"2026-03-15","conditions":"TNBC - Triple-Negative Breast Cancer, TNBC","enrollment":26},{"nctId":"NCT06510556","phase":"NA","title":"Feasibility Study of the FARAFLEX Mapping and PFA System","status":"RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2025-02-17","conditions":"Atrial Fibrillation, Persistent Atrial Fibrillation, Paroxysmal AF","enrollment":250},{"nctId":"NCT04216563","phase":"PHASE2","title":"ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":7},{"nctId":"NCT06911632","phase":"NA","title":"Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tempus AI","startDate":"2025-07-23","conditions":"Pulmonary Hypertension, Interstitial Lung Disease (ILD)","enrollment":1000},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT06457503","phase":"PHASE4","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2024-11-01","conditions":"Nasopharyngeal Cancer Recurrent","enrollment":100},{"nctId":"NCT07442669","phase":"NA","title":"Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration","status":"NOT_YET_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-03-01","conditions":"Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant","enrollment":100},{"nctId":"NCT07444372","phase":"NA","title":"Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-15","conditions":"Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF)","enrollment":658},{"nctId":"NCT05490446","phase":"PHASE2","title":"A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-11-07","conditions":"Myelodysplastic Syndromes","enrollment":87},{"nctId":"NCT05536115","phase":"","title":"Impact of Treatment With ALVEOGYL in Patients With Post-extraction Dry Socket","status":"COMPLETED","sponsor":"Septodont","startDate":"2022-12-13","conditions":"Dry Socket","enrollment":120},{"nctId":"NCT05486559","phase":"NA","title":"The ECMO-Free Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-09-07","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":225},{"nctId":"NCT06540144","phase":"PHASE3","title":"An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2024-10-08","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06523868","phase":"NA","title":"Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2025-03-31","conditions":"Cancer Diagnosis","enrollment":1500},{"nctId":"NCT07382817","phase":"PHASE1","title":"Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-18","conditions":"Neoplasms","enrollment":33},{"nctId":"NCT07108387","phase":"PHASE2","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-11","conditions":"Giant Cell Arteritis (GCA)","enrollment":78},{"nctId":"NCT06414603","phase":"NA","title":"A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Natera, Inc.","startDate":"2024-06-10","conditions":"Heart Transplant Failure and Rejection","enrollment":250},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT03950076","phase":"PHASE4","title":"EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-09-20","conditions":"Intracranial Hemorrhages, Atrial Fibrillation","enrollment":948},{"nctId":"NCT07434284","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of cCTL in Combination With Immunotherapy for Advanced Gynecologic Malignancies","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2026-02","conditions":"Advanced Gynecological Cancers","enrollment":20},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT07432568","phase":"PHASE2","title":"A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT01171898","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2010-07-26","conditions":"Prostate Cancer","enrollment":127},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT05316584","phase":"NA","title":"A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2022-09-06","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":123},{"nctId":"NCT07186595","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-09-25","conditions":"Mid Face Volume Deficit","enrollment":75},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT05239624","phase":"PHASE2","title":"Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-06-02","conditions":"Urothelial Carcinoma","enrollment":23},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT03425526","phase":"PHASE1","title":"Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-15","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised","enrollment":16},{"nctId":"NCT03363373","phase":"PHASE2","title":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","status":"RECRUITING","sponsor":"Y-mAbs Therapeutics","startDate":"2018-04-03","conditions":"Neuroblastoma","enrollment":122},{"nctId":"NCT06118255","phase":"PHASE3","title":"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2024-05-21","conditions":"Dravet Syndrome","enrollment":25},{"nctId":"NCT03557060","phase":"","title":"NUCALA® Special Drug Use Investigation (EGPA, Long-term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis","enrollment":4115},{"nctId":"NCT06483334","phase":"PHASE1, PHASE2","title":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-17","conditions":"Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":38},{"nctId":"NCT05303064","phase":"PHASE3","title":"Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder","status":"RECRUITING","sponsor":"Alkermes, Inc.","startDate":"2022-06-30","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":220},{"nctId":"NCT07272902","phase":"NA","title":"Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2026-01-01","conditions":"Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"At the discretion of the investigator","genericName":"At the discretion of the investigator","companyName":"Institut Bergonié","companyId":"institut-bergoni","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The mechanism of this drug is not specified. Used for At the discretion of the investigator.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}